Compare Taskus Inc (TASK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Taskus Inc trades at $7.59 (market cap $700.49M), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 191.4× Taskus Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| TASK | VRTX | |
|---|---|---|
Market Cap | $700.49M | $134.06B |
Sector | Technology | Health |
52-Week High | $18.03 | $557.96 |
52-Week Low | $4.57 | $376.62 |
Enterprise Value | $1.07B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $7.65, down 3.29% today, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income of $102.28M, yielding attractive valuation ratios including a P/E of 6.59 and P/S of 0.58. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI Services growth.
The stock presents value opportunity with discounted multiples and analyst consensus target of $8.00 (4.6% upside). Risks include client concentration and competitive pressures in digital services. Institutional interest remains positive with Dimensional Fund increasing holdings by 12.8% in Q1 2026.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
